About this event
Featuring expert panels and keynote sessions from EURORDIS leaders, the event fosters collaboration to drive progress in orphan drug development and patient care.
Agenda
October 23 – How will the current OMP amendments affect orphan drug development and patient access? – Virginie Bros-Facer (CEO, EURORDIS)
October 24 – The Rare Disease Action Plan – Where are we, and how can we integrate it from a European to a national level for real impact? – Virginie Bros-Facer (CEO, EURORDIS)
October 25 – Impact of Rare Disease on Mental Health and Wellbeing – Understanding the Link and Improving Outcomes – Matt Bolz-Johnson (Mental Health Lead & Healthcare Advisor, EURORDIS) & Kirsten Johnson (Board Member, EURORDIS)
